Morgan Stanley’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Morgan Stanley’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-390,276	Closed	-$41.9M	–	7758
2023 Q1	$41.9M	Buy	390,276 +231,910	+146%	+$26.7M	﹤0.01%	1705
2022 Q4	$17.4M	Sell	158,366 -11,488	-7%	-$745K	﹤0.01%	2484
2022 Q3	$10M	Buy	169,854 +38,662	+29%	+$1.77M	﹤0.01%	2985
2022 Q2	$3.7M	Buy	131,192 +82,208	+168%	+$2.38M	﹤0.01%	4019
2022 Q1	$1.85M	Buy	48,984 +36,704	+299%	+$1.45M	﹤0.01%	4574
2021 Q4	$486K	Buy	12,280 +9,879	+411%	+$309K	﹤0.01%	5565
2021 Q3	$57K	Sell	2,401 -455	-16%	-$10.7K	﹤0.01%	6665
2021 Q2	$71K	Buy	2,856 +2,567	+888%	+$57.3K	﹤0.01%	6508
2021 Q1	$5K	Buy	+289	New	+$5.97K	﹤0.01%	7125

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Morgan Stanley's RXDX Position: Q2 2023 in Review

Morgan Stanley sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 390,276 shares — an estimated $41.9M sold.

Morgan Stanley first reported a position in RXDX in Q1 2021 and held it in 9 quarters. The position peaked at $41.9M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Morgan Stanley reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Morgan Stanley sold 390,276 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $41.9M.
Morgan Stanley first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2021 and held it in 9 quarters.
Morgan Stanley's Prometheus Biosciences, Inc. Common Stock position peaked at $41.9M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Morgan Stanley's 13F filing for Q2 2023, filed 14 Aug 2023.